FIGO stage IIIC endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival

Robert E. Bristow, M. L. Zahurak, C. J. Alexander, R. C. Zellars, F. J. Montz

Research output: Contribution to journalArticle

Abstract

The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma. Demographic, operative, pathologic, & follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer. Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All patients had positive pelvic lymph nodes and 20 patients (48.8%) had positive para-aortic lymph nodes. Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy. The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months). Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006). On multivariate analysis, independent predictors of DSS were gross residual nodal disease (HR 7.96, 95% CI 2.54-24.97, P <0. 001), age ≥ 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

Original languageEnglish (US)
Pages (from-to)664-672
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume13
Issue number5
DOIs
StatePublished - Sep 2003

Fingerprint

Endometrial Neoplasms
Survival
Radiotherapy
Adjuvant Chemotherapy
Lymph Nodes
Proportional Hazards Models
Multivariate Analysis
Logistic Models
Regression Analysis
Demography
Drug Therapy

Keywords

  • Chemotherapy
  • Lymphadenopathy
  • Radiation therapy
  • Surgery

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

FIGO stage IIIC endometrial carcinoma : Resection of macroscopic nodal disease and other determinants of survival. / Bristow, Robert E.; Zahurak, M. L.; Alexander, C. J.; Zellars, R. C.; Montz, F. J.

In: International Journal of Gynecological Cancer, Vol. 13, No. 5, 09.2003, p. 664-672.

Research output: Contribution to journalArticle

Bristow, Robert E. ; Zahurak, M. L. ; Alexander, C. J. ; Zellars, R. C. ; Montz, F. J. / FIGO stage IIIC endometrial carcinoma : Resection of macroscopic nodal disease and other determinants of survival. In: International Journal of Gynecological Cancer. 2003 ; Vol. 13, No. 5. pp. 664-672.
@article{13c4023726124b649b198205ba660152,
title = "FIGO stage IIIC endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival",
abstract = "The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma. Demographic, operative, pathologic, & follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer. Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All patients had positive pelvic lymph nodes and 20 patients (48.8{\%}) had positive para-aortic lymph nodes. Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy. The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months). Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006). On multivariate analysis, independent predictors of DSS were gross residual nodal disease (HR 7.96, 95{\%} CI 2.54-24.97, P <0. 001), age ≥ 65 years (HR 6.22, 95{\%} CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95{\%} CI 0.07-0.76, P = 0.016). We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.",
keywords = "Chemotherapy, Lymphadenopathy, Radiation therapy, Surgery",
author = "Bristow, {Robert E.} and Zahurak, {M. L.} and Alexander, {C. J.} and Zellars, {R. C.} and Montz, {F. J.}",
year = "2003",
month = "9",
doi = "10.1046/j.1525-1438.2003.13385.x",
language = "English (US)",
volume = "13",
pages = "664--672",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - FIGO stage IIIC endometrial carcinoma

T2 - Resection of macroscopic nodal disease and other determinants of survival

AU - Bristow, Robert E.

AU - Zahurak, M. L.

AU - Alexander, C. J.

AU - Zellars, R. C.

AU - Montz, F. J.

PY - 2003/9

Y1 - 2003/9

N2 - The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma. Demographic, operative, pathologic, & follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer. Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All patients had positive pelvic lymph nodes and 20 patients (48.8%) had positive para-aortic lymph nodes. Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy. The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months). Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006). On multivariate analysis, independent predictors of DSS were gross residual nodal disease (HR 7.96, 95% CI 2.54-24.97, P <0. 001), age ≥ 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

AB - The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma. Demographic, operative, pathologic, & follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer. Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All patients had positive pelvic lymph nodes and 20 patients (48.8%) had positive para-aortic lymph nodes. Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy. The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months). Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006). On multivariate analysis, independent predictors of DSS were gross residual nodal disease (HR 7.96, 95% CI 2.54-24.97, P <0. 001), age ≥ 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

KW - Chemotherapy

KW - Lymphadenopathy

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=1242269313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242269313&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.2003.13385.x

DO - 10.1046/j.1525-1438.2003.13385.x

M3 - Article

C2 - 14675352

AN - SCOPUS:1242269313

VL - 13

SP - 664

EP - 672

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -